Torcetrapib + atorvastatin (Pfizer).
Pfizer is developing a combination tablet containing torcetrapib, a cholesteryl ester transfer protein inhibitor and high-density lipoprotein cholesterol enhancer, and the 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor, atorvastatin, for the potential treatment of atherosclerosis and hypercholesterolemia. As of April 2005, phase III trials were ongoing.
Burnett
John R
JR
Royal Perth Hospital, Department of Core Clinical Pathology & Biochemistry, PathWest Laboratory Medicine WA, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au
D000818:Animals; D050197:Atherosclerosis / Q000097:blood / Q000188:drug therapy*; D000069059:Atorvastatin; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D011758:Pyrroles / Q000008:administration & dosage*; D011804:Quinolines / Q000008:administration & dosage*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004338:Drug Combinations; D006538:Heptanoic Acids; D011758:Pyrroles; D011804:Quinolines; C483909:torcetrapib; D000069059:Atorvastatin